Pharmacy and Poison Board bans Neotack drug
The Kenya Pharmacy and Poisons Board has withdrawn anti-acid Ranitidine drug over concerns that it was linked to cancer in the United States of America.
The anti-acid Ranitidine is known as Neotack in Kenya.
The U.s Food and Drug Administration (FDA) stated that the popular heartburn drug ranitidine contained small amounts N-nitrosodimethylamine (NDMA), which the regulator says is a “probable human carcinogen.
Kenya has joined a list of drug manufacturers across the world have begun recalling the widely taken heartburn drug.